News

Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4. Approximately 214,000 people

Trabodenoson, which is the company’s lead clinical candidate, is being investigated to reduce intraocular pressure. About 335 patients diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

The CRL states that additional clinical information is required to support the company’s new drug application (NDA). It includes clinical trial data from ongoing or completed studies and

The company plans to start a commercial launch of the drug in major European countries in early next year. Earlier this year, the European Medicines Agency’s Committee for

TBRIA is a once-daily oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable

While current HIV treatments involve pills that are taken daily, the new regimens’ long-lasting effects suggest that HIV treatment could be administered perhaps once or twice per year.

Shire has recently completed a Phase 3 study of lifitegrast, OPUS-3, that is expected to be the basis of Shire’s response to the CRL. The FDA also requested

The funding will be used for the study to discover antibodies against Ebola virus and identify how they prevent Ebola virus infection, allowing to develop Ebola therapeutics and

The company said that the results of the trial were not statistically significant, in which the primary endpoint of change from baseline in the six-minute walk test (6MWT)